gabapentin has been researched along with Acute Lymphoid Leukemia in 3 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Excerpt | Relevance | Reference |
---|---|---|
"Children with acute lymphoblastic leukemia (ALL) often experience treatment-related neurocognitive deficits and significant pain." | 3.11 | Neuropathic pain and neurocognitive functioning in children treated for acute lymphoblastic leukemia. ( Alberts, NM; Anghelescu, DA; Conklin, HM; Jacola, LM; Krull, KR; Partanen, M; Pui, CH, 2022) |
" Only the risk classification of acute lymphoblastic leukemia was significantly associated with the daily morphine dosage (P = ." | 2.94 | Prospective randomized trial of interventions for vincristine-related neuropathic pain. ( Anghelescu, DL; Cheng, C; Jeha, S; Pauley, J; Pei, D; Pui, CH; Sandlund, JT; Tesney, JM; Trujillo, L; Wright, BB, 2020) |
"Improved cure rates for childhood acute lymphoblastic leukemia (ALL) over the past 2 decades have allowed greater attention to patients' quality of life." | 1.37 | Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. ( Anghelescu, DL; Cheng, C; Faughnan, LG; Hankins, G; Hinds, PS; Jeha, S; Pauley, JL; Pei, D; Pui, CH; Relling, MV; Sandlund, JT, 2011) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 2 (66.67) | 2.80 |
Authors | Studies |
---|---|
Partanen, M | 1 |
Alberts, NM | 1 |
Conklin, HM | 1 |
Krull, KR | 1 |
Pui, CH | 3 |
Anghelescu, DA | 1 |
Jacola, LM | 1 |
Anghelescu, DL | 2 |
Tesney, JM | 1 |
Jeha, S | 2 |
Wright, BB | 1 |
Trujillo, L | 1 |
Sandlund, JT | 2 |
Pauley, J | 1 |
Cheng, C | 2 |
Pei, D | 2 |
Faughnan, LG | 1 |
Relling, MV | 1 |
Hinds, PS | 1 |
Hankins, G | 1 |
Pauley, JL | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia[NCT00137111] | Phase 3 | 501 participants (Actual) | Interventional | 2000-07-08 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count~Measurement: Percentage change of leukemia cells from baseline" (NCT00137111)
Timeframe: Immediately before the methotrexate infusion and three days after subsequent infusion
Intervention | Percent change (Mean) |
---|---|
4 hr | -44 |
24 hr | -50 |
CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow up time (range) 4.5 (1 to 7.8) years
Intervention | Percentage of participants (Number) |
---|---|
Patients With High Risk of CNS Relapse | 92.2 |
Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells. (NCT00137111)
Timeframe: 42 hours after start of high dose methotrexate infusion (HDMTX)
Intervention | pmol/1,000,000,000 cells (Mean) |
---|---|
4 hr | 1688 |
24 hr | 2521 |
EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow-up time (range) 5.6 (1.3 to 8.9) years
Intervention | Percentage of Participants (Number) |
---|---|
Total Therapy | 87.3 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of CASP1 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
Intervention | arbitrary units (Median) | |
---|---|---|
Prednisolone-sensitive cells | Prednisolone-resistant cells | |
Total Therapy | 341.3 | 447.9 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of NLRP3 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
Intervention | arbitrary units (Median) | |
---|---|---|
Prednisolone-sensitive cells | Prednisolone-resistant cells | |
Total Therapy | 41.2 | 110.7 |
Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (>=0.01%). (NCT00137111)
Timeframe: End of Induction (Day 46 MRD measurement)
Intervention | participants (Number) | |
---|---|---|
Negative <0.01% | Positive >= 0.01% | |
Total Therapy | 390 | 102 |
2 trials available for gabapentin and Acute Lymphoid Leukemia
Article | Year |
---|---|
Neuropathic pain and neurocognitive functioning in children treated for acute lymphoblastic leukemia.
Topics: Analgesics, Opioid; Child; Female; Gabapentin; Humans; Male; Neuralgia; Neuropsychological Tests; Pr | 2022 |
Prospective randomized trial of interventions for vincristine-related neuropathic pain.
Topics: Adolescent; Analgesics; Analgesics, Opioid; Antineoplastic Agents, Phytogenic; Child; Child, Prescho | 2020 |
1 other study available for gabapentin and Acute Lymphoid Leukemia
Article | Year |
---|---|
Neuropathic pain during treatment for childhood acute lymphoblastic leukemia.
Topics: Adolescent; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Child; Child, Preschool; | 2011 |